Laura Fulper Hutchins
Role not yet determined Is this you? Add your title
Also affiliated: Inje University (2009–2010); Tufts Medical Center (2005); Roswell Park Comprehensive Cancer Center (2009–2010); City Of Hope National Medical Center (1994); Loyola University Medical Center (2004); Cleveland Clinic (2005); Sunnybrook Health Science Centre (2005); Mayo Clinic (2007); Memorial Sloan Kettering Cancer Center (2003); University of Arizona (2009–2010); Emory University (2009); University of California, Los Angeles (2003–2008); Oregon Health & Science University (1993–2005); The University of Texas at San Antonio Health Science Center (2005); University of Pittsburgh (2008); University of California, San Francisco (2003); Baylor College of Medicine (2003–2009); Georgetown University (2003); Loyola University Chicago (1996–2009); University of Washington (2004); University of Michigan (1993–2004); University Hospitals of Cleveland (2005); Saint Francis Memorial Hospital (2009); University of Arkansas Medical Center (2001–2021); University of Arkansas System (2012); Johns Hopkins Medicine (2005); Allegheny General Hospital (2008); Providence Portland Medical Center (2017); Missouri Baptist Medical Center (2005); University of Colorado Health (2009); Fred Hutch Cancer Center (2004); Shadyside Hospital (2008); Central Arkansas Veterans Healthcare System (2005); Angeles Clinic and Research Institute (2007–2010); Magee-Womens Hospital (2008); Michigan Medicine (1993–2004); Dana-Farber Cancer Institute (2003–2007); UPMC Hillman Cancer Center (2008); John L. McClellan Memorial Veterans Hospital (1985–1999); Synta Pharmaceuticals (United States) (2009); Loyola Medicine (2008–2009); Aultman Health Foundation (2008); SWOG Cancer Research Network (1994–2008); University of Arizona Cancer Center (2010); U-M Rogel Cancer Center (2010); UCLA Jonsson Comprehensive Cancer Center (2008); Winship Cancer Institute (2009); University of Colorado Anschutz (2009); University of Cincinnati (2005); University at Buffalo, State University of New York (2009); University of Missouri (2009); Columbia University (2009); University of California, Davis (2005)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Laura F. Hutchins' research focuses on cancer treatment and patient outcomes, with a particular emphasis on breast cancer and melanoma. Her work investigates disparities in cancer care and treatment adherence, utilizing large datasets such as state cancer registries and all-payer claims databases. Recent publications include analyses of racial disparities in adherence to endocrine therapy for early-stage hormone receptor-positive breast cancer, and consistency in reporting radiation therapy data after breast-conserving surgery.
Hutchins also examines adverse events associated with cancer therapies, such as immune adverse events (irAEs) in patients receiving adjuvant ipilimumab for melanoma. Her research explores the use of immunosuppressants and their association with treatment outcomes in these cases. She has published 153 works, accumulating over 9,700 citations, and holds an h-index of 44, reflecting a significant impact in her field. She leads a research group and maintains an active lab website.
Metrics
- h-index: 44
- Publications: 153
- Citations: 9,779
Selected Publications
-
Racial Disparity in Adherence to Endocrine Therapy among Women with Early-Stage Hormone Receptor Positive Breast Cancer: An Analysis of Arkansas All-Payers Claims Database (2024)
-
Consistency Between State's Cancer Registry and All-Payer Claims Database in Documented Radiation Therapy Among Patients Who Received Breast Conservative Surgery (2023)
-
Reporting consistency in radiation therapy after breast conservative surgery between Arkansas Cancer Registry and all payers claims database. (2022)
-
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis (2021)
-
312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition (2020)
-
Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study (2020)
-
Abstract P3-09-18: Immunization of breast cancer patients in combination with standard-of-care chemotherapy: Results of a phase Ib clinical trial (2020)
-
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609 (2019)
-
In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma (2019)
-
United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma. (2019)
-
Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study (2019)
-
Cancer patient perspectives regarding preparedness for end-of-life care: A qualitative study (2018)
-
Liquid biopsy and its role in an advanced clinical trial for lung cancer (2018)
-
Outcomes of immunotherapy in advanced melanoma in relation to age. (2018)
-
Metastatic melanoma with dedifferentiation and extensive rhabdomyosarcomatous heterologous component (2018)
Collaboration Network
Top Collaborators
- In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma
- Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer
- Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Showing 5 of 21 shared publications
- Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma
- Pre-diagnosis blood glucose and prognosis in women with breast cancer
- Moving a Carbohydrate Mimetic Peptide into the clinic
Showing 5 of 11 shared publications
- Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors
- Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
- Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
- Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature
- Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better
Showing 5 of 11 shared publications
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma
- Pre-diagnosis blood glucose and prognosis in women with breast cancer
- Moving a Carbohydrate Mimetic Peptide into the clinic
- Harnessing benefit from targeting tumor associated carbohydrate antigens
Showing 5 of 9 shared publications
- In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- Pre-diagnosis blood glucose and prognosis in women with breast cancer
- Moving a Carbohydrate Mimetic Peptide into the clinic
- Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients
Showing 5 of 9 shared publications
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
- A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Evaluation of Cisplatin and DTIC in Inoperable Stage III and IV Melanoma
- Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508
Showing 5 of 8 shared publications
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
- Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897
- A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316)
- Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
- Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base
Showing 5 of 8 shared publications
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma
- Pre-diagnosis blood glucose and prognosis in women with breast cancer
- Moving a Carbohydrate Mimetic Peptide into the clinic
- Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study
Showing 5 of 7 shared publications
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
- A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508
- United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
Showing 5 of 7 shared publications
- Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- Moving a Carbohydrate Mimetic Peptide into the clinic
- Harnessing benefit from targeting tumor associated carbohydrate antigens
- Managing Expectations in the Transition to Proof of Concept Studies
Showing 5 of 7 shared publications
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
- A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508
- United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
Showing 5 of 6 shared publications
- Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897
- Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
- Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base
- Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer
- Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A southwest oncology group study
Showing 5 of 6 shared publications
- Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism.
- Association between a glutathione S‐transferase A1 promoter polymorphism and survival after breast cancer treatment
- Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
- Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer
- Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study
Showing 5 of 6 shared publications
- Liquid biopsy and its role in an advanced clinical trial for lung cancer
- Cancer patient perspectives regarding preparedness for end-of-life care: A qualitative study
- Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor
- Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program
- Abstract 2889: Human antibodies induced by vaccination with a carbohydrate mimetic-peptide vaccine show functional anti-tumor activity on human lung-cancer cells
- Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897
- Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
- Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer
- Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study
- Abstract 2032: Germline genetic variants in GATA3 and breast cancer treatment outcomes in SWOG 8897 trial
Similar Researchers
Based on overlapping research topics